open access

Vol 5, No 2 (2016)
Review articles (submitted)
Published online: 2016-07-06
Get Citation

Cardiovascular safety of SGLT2 inhibitors

Janusz Gumprecht
DOI: 10.5603/DK.2016.0007
·
Clinical Diabetology 2016;5(2):62-65.

open access

Vol 5, No 2 (2016)
Review articles (submitted)
Published online: 2016-07-06

Abstract

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, also called flozins, are a new group of oral antidiabetic drugs. Due to progressive nature of type 2 diabetes and gradual deterioration of pancreatic beta cell function, achieving good diabetes control still remains a challenge. This stimulates researchers and clinicians to search for new directions in diabetes treatment and to develop optimal antidiabetic therapy. Particularly interesting in this context are (besides incretin-based therapies) SGLT2, because they reduce renal glucose reabsorption and, thereby, increase urinary glucose excretion. Their action is independent from an insulin, both in terms of an insulin secretion and action. Type 2 diabetes remains one of the major cardiovascular risk factors. The most important issue related to this group of drugs is therefore establishing the principles of safe, well-tolerated and effective long-term treatment of patients with vascular complications of various severity, including cardiovascular complications mainly. New antidiabetic drugs should not only improve glycaemic control, but also contribute to the reduction of cardiovascular morbidity and mortality.

Abstract

Sodium-glucose co-transporter-2 (SGLT2) inhibitors, also called flozins, are a new group of oral antidiabetic drugs. Due to progressive nature of type 2 diabetes and gradual deterioration of pancreatic beta cell function, achieving good diabetes control still remains a challenge. This stimulates researchers and clinicians to search for new directions in diabetes treatment and to develop optimal antidiabetic therapy. Particularly interesting in this context are (besides incretin-based therapies) SGLT2, because they reduce renal glucose reabsorption and, thereby, increase urinary glucose excretion. Their action is independent from an insulin, both in terms of an insulin secretion and action. Type 2 diabetes remains one of the major cardiovascular risk factors. The most important issue related to this group of drugs is therefore establishing the principles of safe, well-tolerated and effective long-term treatment of patients with vascular complications of various severity, including cardiovascular complications mainly. New antidiabetic drugs should not only improve glycaemic control, but also contribute to the reduction of cardiovascular morbidity and mortality.

Get Citation

Keywords

SGLT2 inhibitors, cardiovascular safety, type 2 diabetes

About this article
Title

Cardiovascular safety of SGLT2 inhibitors

Journal

Clinical Diabetology

Issue

Vol 5, No 2 (2016)

Pages

62-65

Published online

2016-07-06

DOI

10.5603/DK.2016.0007

Bibliographic record

Clinical Diabetology 2016;5(2):62-65.

Keywords

SGLT2 inhibitors
cardiovascular safety
type 2 diabetes

Authors

Janusz Gumprecht

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl